Allarity Therapeutics, Inc. - ALLR STOCK NEWS

Allarity Therapeutics, Inc. (Nasdaq: ALLR) announced that CEO James G. Cullem will present a corporate update on September 29, 2022, at the Ladenburg Thalmann Healthcare Conference in New York. The presentation is scheduled for 3:00 p.m. ET. Investors interested in one-on-one meetings can reach out via Ladenburg Thalmann or email the company. A webcast of the presentation will be available on the company's website for 30 days following the event. Allarity develops personalized cancer therapies using its proprietary DRP® diagnostic platform, which enhances treatment efficacy.

Allarity Therapeutics, Inc. (Nasdaq: ALLR) announced the appointment of Wolf & Company as its independent public accounting firm, effective immediately. This change follows the resignation of Marcum LLP on August 5, 2022. While the new appointment does not immediately affect compliance with Nasdaq Listing Rule 5250(c)(1), it is a crucial step in regaining compliance. Allarity is working with Wolf & Company to file its Quarterly Report on Form 10-Q for Q2 2022, which is essential for regaining Nasdaq compliance. The company focuses on developing oncology therapeutics supported by its DRP® companion diagnostics.

On August 26, 2022, Allarity Therapeutics (Nasdaq: ALLR) disclosed receipt of a non-compliance letter from Nasdaq regarding its failure to file the Quarterly Report on Form 10-Q for the quarter ending June 30, 2022. This notification does not immediately affect the company's stock listing but poses a risk of delisting if compliance is not restored. The company has 60 days to submit a plan, and if accepted, may have up to 180 days to file the report. Allarity aims to file the Form 10-Q as soon as possible, maintaining focus on its oncology drug development.

Allarity Therapeutics, Inc. has refocused its oncology pipeline strategy from monotherapy to combination therapies. This shift aims to align with the growing standard of care in oncology, optimize funding opportunities, and enhance commercial prospects. The Board's decision follows feedback from the FDA indicating the need for additional studies on dovitinib's dosing before proceeding to Phase 3 trials. The company plans to initiate a Phase 1b/2 study of stenoparib in combination with dovitinib for ovarian cancer by Q4 2022. Ongoing studies for stenoparib and IXEMPRA will continue as planned.

Allarity Therapeutics, Inc. announced the appointment of David A. Roth, M.D., as a new board member, effective July 7, 2022. Interim CEO James G. Cullem and co-founder Thomas Jensen also joined the board. Dr. Roth brings over 25 years of experience in oncology drug development, enhancing Allarity's strategy in personalized cancer care through its Drug Response Predictor (DRP®) companion diagnostics. The DRP® platform has shown significant predictive ability in clinical outcomes across multiple studies, underscoring Allarity's commitment to improving therapeutic response rates for cancer patients.

Allarity Therapeutics has appointed James G. Cullem, J.D., as interim CEO and Joan Y. Brown, CPA, as interim CFO, following the resignation of former CEO Steve R. Carchedi and CFO Jens Knudsen. The leadership transition aims to prepare the company for future growth. Cullem, with over 20 years in life sciences, has been with Allarity since 2014, focusing on the acquisition of key oncology assets. Brown brings extensive financial reporting experience, contributing to Allarity's Nasdaq listing. The board anticipates naming permanent executives in the first half of 2023.

Allarity Therapeutics has announced the appointment of Dr. Roberto Pili to its Scientific Advisory Board. With extensive expertise in renal cancers and personalized medicine, Dr. Pili will contribute to advancing Allarity's clinical programs. The company specializes in oncology therapeutics and uses its proprietary Drug Response Predictor (DRP) companion diagnostics to enhance treatment efficacy. Dr. Pili's experience includes conducting clinical trials and publishing over 200 peer-reviewed articles. Allarity aims to improve cancer treatment outcomes through innovative therapies guided by individualized patient diagnostics.

Allarity Therapeutics reported their Q1 2022 financial results, showing a net loss of $3.1 million, unchanged from Q1 2021. Their cash reserves declined to $14.5 million from $19.6 million in the previous quarter. R&D expenses remained flat at $1.3 million year over year, while G&A expenses rose significantly to $3.0 million from $1.2 million. The company recorded a notable $14.0 million impairment of intangible assets, compared to none in the prior year. Allarity continues to advance its pipeline for personalized cancer therapies using its DRP® companion diagnostics.

Allarity Therapeutics (NASDAQ: ALLR) corrected a typographical error in its press release dated May 16, 2022. The company stated that the debt cancellation amount was incorrectly reported as "$971 million" instead of "$971 thousand." This debt cancellation exempts Allarity from future financial obligations related to the LiPlaCis® program, allowing for potential milestone payments of up to $3.5 million. The company is focused on developing personalized cancer treatments using its Drug Response Predictor (DRP®) companion diagnostic technology.